Endogenous Toxins: Targets for Disease Treatment and Prevention, 2 Volume Set

PART A: ENDOGENOUS TOXINS ASSOCIATED WITH EXCESSIVE SUGAR, FAT, RED MEAT OR ALCOHOL CONSUMPTION
1: Endogenous DNA damage
2: Modification of cysteine residues in protein
3: Endogenous macromolecule radicals
4: Alcohol-derived bioadducts
5: Iron from meat produces endogenous pro-carcinogen peroxides
6: Short chain sugars as endogenous toxins
7: Fructose-derived endogenous toxins
8: Cytotoxicity and oxidative stress induced by the glyceraldehyde-related Maillard reaction products
9: Estrogens as Endogenous Toxins
10: Reactive oxygen species (ROS), hypohalites (HOCI), and reactive nitrogen species (NOS)

PART B: GENETICS, ENDOGENOUS TOXINS ASSOCIATED WITH INBORN ERRORS OF METABOLISM
11: Oxalate and primary hyperoxaluria
12: Pathophysiology of endogenous toxins and their relation to in-born errors of metabolism and drug mediated toxicities
13: Mechanisms of toxicity in fatty acid oxidation disorders
14: Homocysteine as an endogenous toxin in cardiovascular disease
15: Uric acid alterations in cardiometabolic disorders and gout
16: Genetic defects in iron and copper trafficking
17: Polyglutamine neuropathies: Animal models to molecular mechanisms

PART C: EXAMPLES OF ENDOGENOUS TOXINS ASSOCIATED WITH ACQUIRED DISEASES OR ANIMAL DISEASE MODELS
18: Alcohol-induced hepatic injury
19: Ethanol-induced endotoxemia and tissue injury
20: Gut microbiota, diet, endotoxemia and disease
21: Nutrient derived endogenous toxins in the pathogenesis of Type 2 diabetes at the beta cell level
22: Endogenous toxins and susceptibility or resistance to diabetes complications
23: Serum advanced glycation end products associated with NASH and other liver diseases
24: Oxidative stress in the pathogenesis of hepatitis C
25: Oxidised low density lipoprotein cytotoxicity and vascular disease
26: Oxidative stress in breast cancer carcinogenesis
27: Lifestyle, endogenous toxins and colorectal cancer risk
28: Dopamine-derived neurotoxins and Parkinson's disease
29: Dopamine catabolism and Parkinson's disease: Role of a reactive aldehyde intermediate
30: Tetrahydropapaveroline, an endogenous dicatechol isoquinoline
31: Chemically-induced autoimmunity
32: Endogenous toxins associated with life expectancy and aging

PART D: THERAPEUTICS PROPOSED FOR DECREASING ENDOGENOUS TOXINS
33: Therapeutic potentials for decreasing the endogenous toxin homocysteine: Clinical trials
34: Prevention of oxidative stress-induced disease by natural dietary compounds: The mechanism of actions
35: Genotoxicity of endogenous estrogens
36: Design of nutritional interventions for control of cellular oxidation